AngioDynamics Receives 510(k) Clearance for AlphaVac F18⁸⁵ System in Treatment of PE

Go back to AngioDynamics Receives 510(k) Clearance for AlphaVac F18⁸⁵ System in Treatment of PE

Oppenheimer Upgrades AngioDynamics (ANGO) to Outperform

April 5, 2024 7:02 AM EDT

Oppenheimer analyst Steven M. Lichtman upgraded AngioDynamics (NASDAQ: ANGO) from Perform to Outperform with a price target of $12.00.

The analyst comments "We are upgrading ANGO shares from Perform to Outperform with a $12 PT based on the following: 1) Yesterday's earlier than expected FDA approval... More